Advancing innovative therapies against pandrug-resistant Gram-negative superbugs
推进针对全耐药革兰氏阴性超级细菌的创新疗法
基本信息
- 批准号:10189507
- 负责人:
- 金额:$ 64.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAcinetobacter baumanniiAddressAdverse effectsAerosolsAmikacinAnti-Bacterial AgentsAntibioticsAntimicrobial ResistanceBronchial SpasmCellsCiprofloxacinClinicClinicalClinical ResearchColistinCombined AntibioticsCombined Modality TherapyConfocal MicroscopyCoughingDataDevelopmentDoseDose-LimitingDrug ExposureDrug KineticsEncapsulatedEpithelialEpithelial CellsEvolutionFluorescence MicroscopyFormulationFourier TransformFreeze DryingFundingHealthHumanImageImaging TechniquesIn VitroInfectionInhalationInhalation TherapyInnovative TherapyIonsKlebsiella pneumoniaeLeadLiposomesLower Respiratory Tract InfectionLungLung infectionsMass Spectrum AnalysisMesylatesMetalsMicrobial BiofilmsModelingMonte Carlo MethodMulti-Drug ResistanceMusNational Institute of Allergy and Infectious DiseaseNebulizerPenetrationPerformancePharmaceutical PreparationsPharmacodynamicsPharmacologyPharmacotherapyPolymersPolymyxin ResistancePolymyxinsPowder dose formProdrugsProductionPseudomonas aeruginosaPulmonary TuberculosisRegimenResearch PriorityResistanceResortRespiratory Tract InfectionsRodentRoentgen RaysRouteSiteSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationSuperbugSurfaceSynchrotronsSystemTechniquesTechnologyTissue ModelToxic effectTranslatingTreatment EfficacyUnited States National Institutes of HealthVariantWorkWorld Health Organizationamphiphilicityantimicrobialbasecombatcompliance behaviorcontrolled releasedosagedrug dispositiondrug inhalationeffective therapyefficacious treatmentglobal healthimaging systemin vivoinnovationinterdisciplinary approachmultidisciplinarynanoscalenephrotoxicitynovelnovel strategiesnovel therapeuticspathogenpathogenic bacteriapublic health relevancerespiratorysuccesstreatment strategy
项目摘要
The World Health Organization (WHO) has recently listed Gram-negative ‘superbugs’ Klebsiella pneumoniae,
Pseudomonas aeruginosa, and Acinetobacter baumannii as the most critical pathogens, which are the greatest
threat to human health. Due to the slow progress in development of novel antibiotics, polymyxins are often used
as the last-line therapy against Gram-negative infections; however, clinical studies have shown that the efficacy
of parenteral polymyxins is disappointing for the treatment of Gram-negative lung infections due to very low
exposure of the drug to the infection site at the airway surface and dose-limiting kidney toxicity. More worrying
is the development of polymyxin resistance induced by the polymyxin monotherapy. One of the promising
strategies for the treatment of Gram-negative lung infections is direct delivery of synergistic polymyxin
combinations to the infection sites at the airway surface. However, conventional nebulization has low delivery
efficiency; even worse, current colistin methanesulfonate (CMS) nebulization therapies are empirical and have
never been systematically optimized using pharmacokinetic/pharmacodynamic/toxicodynamic (PK/PD/TD).
The overall aim of this project is to develop novel liposomal therapies for combinational antibiotics using
innovative spray-freeze-drying powder production technology, cutting-edge imaging, systems pharmacology and
mechanism-based pharmacokinetic/pharmacodynamic/toxicodynamic (PK/PD/TD) modeling. The Specific
Aims are: (1) to develop novel liposomal formulations of polymyxin combinations using innovative spray-freeze-
drying technology; (2) to determine in vitro pharmacodynamics of the formulations; (3) to elucidate the disposition
of polymyxin combinations from the formulations in the airway using cutting-edge imaging and the mechanisms
of potential pulmonary toxicities using systems pharmacology; (4) to apply mechanism-based PK/PD/TD
modeling to optimizing dosage regimens of the superior liposomal formulation in rodent lung infection models.
To combat the emergent global antimicrobial crisis, we must outpace the evolution of ‘superbugs’ by novel
strategies. With the disappointing progress in developing new antibiotic against MDR Gram-negative pathogens,
our innovative multi-disciplinary project addresses NIAID’s strategic approach “extending the clinical
utility of antibacterial drugs̸optimizing use of existing drugs and combination therapies to suppress
emergence of resistance and minimize toxicity”. The success of our work will have a broader impact to the
USA and global health as the platform can be readily applied to develop superior new therapies for other
respiratory infections such as pulmonary tuberculosis.
世界卫生组织(WHO)最近将革兰氏阴性“超级细菌”肺炎克雷伯菌列入名单,
铜绿假单胞菌和鲍曼不动杆菌是最重要的致病菌,是最大的致病菌。
对人类健康的威胁。由于新型抗生素的开发进展缓慢,经常使用多粘菌素
作为对抗革兰氏阴性菌感染的最后一线疗法;但临床研究表明,其功效
肠外多粘菌素对革兰氏阴性肺部感染的治疗效果令人失望,因为其浓度非常低。
药物暴露于气道表面的感染部位和剂量限制性肾毒性。更令人担忧
是由多粘菌素单一疗法引起的多粘菌素耐药性的发展。有希望的之一
治疗革兰氏阴性肺部感染的策略是直接递送协同多粘菌素
组合到气道表面的感染部位。然而,传统雾化的输送量较低
效率;更糟糕的是,目前的甲磺酸粘菌素 (CMS) 雾化疗法是经验性的,并且
从未使用药代动力学/药效学/毒效动力学(PK/PD/TD)进行系统优化。
该项目的总体目标是开发用于组合抗生素的新型脂质体疗法
创新的喷雾冷冻干燥粉末生产技术、尖端成像、系统药理学和
基于机制的药代动力学/药效学/毒效动力学(PK/PD/TD)建模。具体
目标是:(1)使用创新的喷雾冷冻技术开发多粘菌素组合的新型脂质体制剂
干燥技术; (2)测定制剂的体外药效学; (3) 阐明处置
使用尖端成像和机制研究气道制剂中的多粘菌素组合
使用系统药理学研究潜在的肺部毒性; (4)应用基于机制的PK/PD/TD
在啮齿动物肺部感染模型中建立模型以优化优质脂质体制剂的剂量方案。
为了应对新出现的全球抗菌危机,我们必须以新颖的方式超越“超级细菌”的进化
策略。随着针对耐多药革兰氏阴性病原体的新型抗生素的开发进展令人失望,
我们创新的多学科项目解决了 NIAID 的战略方法“扩展临床
抗菌药物的效用——优化现有药物和联合疗法的使用以抑制
抗性的出现并最大限度地减少毒性”。我们工作的成功将对
美国和全球健康作为平台可以很容易地应用于为其他国家开发优质的新疗法
呼吸道感染,例如肺结核。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jian Li其他文献
Jian Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jian Li', 18)}}的其他基金
Do long working hours increase the risk of cardiovascular disease mortality? Evidence from the U.S. National Health Interview Survey 1997-2015
长时间工作会增加心血管疾病死亡风险吗?
- 批准号:
10509317 - 财政年份:2023
- 资助金额:
$ 64.62万 - 项目类别:
Towards the Translation of Synergistic Phage-Polymyxin Combination Therapy against Pandrug-resistant Klebsiella pneumoniae: A Systems Approach
针对泛耐药肺炎克雷伯菌的协同噬菌体-多粘菌素联合疗法的转化:系统方法
- 批准号:
10470088 - 财政年份:2021
- 资助金额:
$ 64.62万 - 项目类别:
Roles of heat shock transcriptional factor 1 in cell proliferation independent of the heat shock response
热休克转录因子 1 在细胞增殖中的作用与热休克反应无关
- 批准号:
10796280 - 财政年份:2020
- 资助金额:
$ 64.62万 - 项目类别:
Roles of heat shock transcriptional factor 1 in cell proliferation independent of the heat shock response
热休克转录因子 1 在细胞增殖中的作用与热休克反应无关
- 批准号:
10699046 - 财政年份:2020
- 资助金额:
$ 64.62万 - 项目类别:
Roles of heat shock transcriptional factor 1 in cell proliferation independent of the heat shock response
热休克转录因子 1 在细胞增殖中的作用与热休克反应无关
- 批准号:
10701882 - 财政年份:2020
- 资助金额:
$ 64.62万 - 项目类别:
Roles of heat shock transcriptional factor 1 in cell proliferation independent of the heat shock response
热休克转录因子 1 在细胞增殖中的作用与热休克反应无关
- 批准号:
10251924 - 财政年份:2020
- 资助金额:
$ 64.62万 - 项目类别:
Roles of heat shock transcriptional factor 1 in cell proliferation independent of the heat shock response
热休克转录因子 1 在细胞增殖中的作用与热休克反应无关
- 批准号:
10028798 - 财政年份:2020
- 资助金额:
$ 64.62万 - 项目类别:
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs
推进针对全耐药革兰氏阴性超级细菌的创新疗法
- 批准号:
10641847 - 财政年份:2019
- 资助金额:
$ 64.62万 - 项目类别:
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs
推进针对全耐药革兰氏阴性超级细菌的创新疗法
- 批准号:
10441316 - 财政年份:2019
- 资助金额:
$ 64.62万 - 项目类别:
Targeting the Urgent Need for New Antibiotics against Gram-negative ‘Superbugs’
针对针对革兰氏阴性“超级细菌”的新型抗生素的迫切需求
- 批准号:
10219081 - 财政年份:2017
- 资助金额:
$ 64.62万 - 项目类别:
相似海外基金
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 64.62万 - 项目类别:
Research Grant
Generative machine learning for narrow spectrum antibiotic discovery against Acinetobacter baumannii
生成机器学习用于发现针对鲍曼不动杆菌的窄谱抗生素
- 批准号:
477936 - 财政年份:2023
- 资助金额:
$ 64.62万 - 项目类别:
Operating Grants
Conserved structural dynamics of outer-membrane channels in Acinetobacter baumannii as potential drug targets
鲍曼不动杆菌外膜通道的保守结构动力学作为潜在的药物靶点
- 批准号:
494854 - 财政年份:2023
- 资助金额:
$ 64.62万 - 项目类别:
Operating Grants
Defining key players at the host-pathogen interface during Acinetobacter baumannii infection
定义鲍曼不动杆菌感染期间宿主-病原体界面的关键参与者
- 批准号:
488684 - 财政年份:2023
- 资助金额:
$ 64.62万 - 项目类别:
Operating Grants
Study of clinically over-expressed and chimeric RND multidrug efflux pumps from Acinetobacter baumannii and Pseudomonas aeruginosa
鲍曼不动杆菌和铜绿假单胞菌临床过表达和嵌合 RND 多药外排泵的研究
- 批准号:
23K14346 - 财政年份:2023
- 资助金额:
$ 64.62万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia
仿生巨噬细胞膜包被的纳米海绵:一种治疗多重耐药铜绿假单胞菌和鲍曼不动杆菌医院相关肺炎的新疗法
- 批准号:
10674406 - 财政年份:2023
- 资助金额:
$ 64.62万 - 项目类别:
Using strain history to improve prediction of the evolution of antimicrobial resistance in Acinetobacter baumannii
利用菌株历史改进对鲍曼不动杆菌抗菌药物耐药性演变的预测
- 批准号:
10677362 - 财政年份:2023
- 资助金额:
$ 64.62万 - 项目类别:
Inhibitors of adaptive efflux mediated resistance in Acinetobacter baumannii
鲍曼不动杆菌适应性外排介导的耐药性抑制剂
- 批准号:
10625029 - 财政年份:2023
- 资助金额:
$ 64.62万 - 项目类别:
Identifying niche specific adaptations in Acinetobacter baumannii
鉴定鲍曼不动杆菌的生态位特异性适应
- 批准号:
10596620 - 财政年份:2022
- 资助金额:
$ 64.62万 - 项目类别:
Identifying niche specific adaptations in Acinetobacter baumannii
鉴定鲍曼不动杆菌的生态位特异性适应
- 批准号:
10449699 - 财政年份:2022
- 资助金额:
$ 64.62万 - 项目类别: